NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
NYSE · MCK · USD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
McKesson Corporation’s quoted price sits in the upper half of its reported 52-week range, 4.79% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
McKesson Corporation’s forward annual dividend is $3.76 per share, paid quarterly. The forward yield is 0.38% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
McKesson Corporation’s next earnings report is currently expected on Nov 4, 2026, with estimated earnings per share of $10.72. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow McKesson Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
McKesson Corporation is a prominent global provider of healthcare services, operating extensively in both the United States and international markets. Its diverse operations are strategically organized into four key business segments. The U.S. Pharmaceutical division plays a crucial role in the distribution of a comprehensive array of pharmaceutical products, encompassing branded, generic, specialty, biosimilar, and over-the-counter medications, alongside other health-related merchandise. This segment also delivers specialized support to community-based oncology and other specialty medical practices through practice management tools, technology solutions, clinical guidance, and broader business services. Furthermore, it assists pharmacies with consulting, outsourcing, and technology services, while also furnishing financial, operational, and clinical software solutions. Internationally, the company's dedicated segment provides distribution and support services to wholesale, institutional, and retail clients across 13 European nations and Canada. The Medical-Surgical Solutions unit is focused on supplying healthcare providers with essential medical-surgical products, sophisticated logistics management, and a variety of associated services. Finally, the Prescription Technology Solutions (RxTS) segment is designed to address complex medication challenges for patients. It collaborates with biopharmaceutical companies and life sciences partners to improve patient journeys, leveraging innovative solutions for medication access and adherence by connecting pharmacies, healthcare providers, payers, and biopharma entities. This segment further offers third-party logistics and wholesale distribution assistance. Founded in 1833, McKesson Corporation maintains its corporate headquarters in Irving, Texas.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:34 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q4 2025 | May 8, 2025 | $10.12+2.95% vs estimate | $90.82B-3.69% vs estimate |
|---|
| Q3 2025 | Feb 5, 2025 | $8.03-6.63% vs estimate | $95.29B-0.79% vs estimate |
|---|
| Q2 2025 | Nov 6, 2024 | $7.07+2.76% vs estimate | $93.65B+4.84% vs estimate |
|---|
THE ANALYST VIEW
31 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 8 contributors · Median target $988.50.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$275.20+$4.16 (+1.53%)
Johnson & Johnson’s quoted price sits in the upper half of its reported 52-week range, 2.09% below the high.
$290.97+$4.98 (+1.74%)
AbbVie Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.55% below the high.
$330.53+$6.18 (+1.91%)
Cencora, Inc.’s quoted price sits in the upper half of its reported 52-week range, 12.45% below the high.
$251.09+$6.33 (+2.59%)
Cardinal Health, Inc.’s quoted price sits in the upper half of its reported 52-week range, 3.13% below the high.
A$2.73+A$0.01 (+0.37%)
Sigma Healthcare Limited’s quoted price sits in the lower half of its reported 52-week range, 14.69% below the high.
CN¥16.45+CN¥0.02 (+0.12%)
Shanghai Pharmaceuticals Holding Co., Ltd’s quoted price sits in the lower half of its reported 52-week range, 11.37% below the high.
HK$16.19+HK$0.27 (+1.7%)
Sinopharm Group Co. Ltd.’s quoted price sits in the lower half of its reported 52-week range, 27.53% below the high.
